{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T08:14:47Z","timestamp":1762157687894,"version":"3.40.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.ejphar.2012.11.026","type":"journal-article","created":{"date-parts":[[2012,11,29]],"date-time":"2012-11-29T23:02:06Z","timestamp":1354230126000},"page":"40-47","source":"Crossref","is-referenced-by-count":8,"title":["Antithrombotic and anticoagulant effects of direct factor Xa inhibitor darexaban in rat and rabbit models of venous thrombosis"],"prefix":"10.1016","volume":"699","author":[{"given":"Seiji","family":"Kaku","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minori","family":"Saitoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Iwatsuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Funatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomihisa","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2012.11.026_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-200464001-00002","article-title":"Current options in the prevention of thromboembolic disease","volume":"64","author":"Ansell","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2012.11.026_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1538-7836.2011.04321.x","article-title":"Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa","volume":"9","author":"Bauer","year":"2011","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.ejphar.2012.11.026_bib3","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1055\/s-2001-17961","article-title":"How and when to monitor a patient treated with low molecular weight heparin","volume":"27","author":"Boneu","year":"2001","journal-title":"Semin. Thromb. Haemostasis"},{"key":"10.1016\/j.ejphar.2012.11.026_bib4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1600-0609.1997.tb01667.x","article-title":"The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls","volume":"58","author":"Burgess","year":"1997","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.ejphar.2012.11.026_bib5","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2012.11.026_bib6","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1111\/j.1538-7836.2007.02644.x","article-title":"A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery","volume":"5","author":"Eriksson","year":"2007","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.ejphar.2012.11.026_bib7","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1538-7836.2010.03748.x","article-title":"Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2)","volume":"8","author":"Eriksson","year":"2010","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.ejphar.2012.11.026_bib8","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1055\/s-0038-1645193","article-title":"Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats","volume":"63","author":"Freund","year":"1990","journal-title":"Thromb. Haemostasis"},{"key":"10.1016\/j.ejphar.2012.11.026_bib9","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/01.CIR.99.1.e1","article-title":"Evaluation of platelet membrane glycoproteins in coronary artery disease: consequences for diagnosis and therapy","volume":"99","author":"Gawaz","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2012.11.026_bib10","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.2174\/1381612033453901","article-title":"Recent advances in the discovery and development of direct coagulation factor Xa inhibitors","volume":"9","author":"Gould","year":"2003","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejphar.2012.11.026_bib11","article-title":"The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4","author":"Groenendaal","year":"2012","journal-title":"Br. J. Clin. Pharmacol"},{"key":"10.1016\/j.ejphar.2012.11.026_bib12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0049-3848(00)00399-6","article-title":"The direct thrombin inhibitor melagatran and its oral prodrug H 376\/95: intestinal absorption properties, biochemical and pharmacodynamic effects","volume":"101","author":"Gustafsson","year":"2001","journal-title":"Thromb. Res."},{"key":"10.1016\/j.ejphar.2012.11.026_bib13","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1161\/01.RES.79.3.590","article-title":"Biochemical and pharmacological properties of SANORG 32701. Comparison with the \u201csynthetic pentasaccharide\u2019 (SR 90107\/ORG 31540) and standard heparin","volume":"79","author":"Herbert","year":"1996","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2012.11.026_bib14","doi-asserted-by":"crossref","first-page":"8051","DOI":"10.1021\/jm200868m","article-title":"Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor","volume":"54","author":"Hirayama","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2012.11.026_bib15","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199105303242206","article-title":"Heparin","volume":"324","author":"Hirsh","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2012.11.026_bib16","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1042\/bj1930395","article-title":"The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin","volume":"193","author":"Holmer","year":"1981","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejphar.2012.11.026_bib17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2011.10.009","article-title":"Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor","volume":"673","author":"Iwatsuki","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2012.11.026_bib18","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0022-3565(25)11073-2","article-title":"Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis","volume":"261","author":"Jackson","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2012.11.026_bib19","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/29325","article-title":"A dual thrombin receptor system for platelet activation","volume":"394","author":"Kahn","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2012.11.026_bib20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0049-3848(03)00094-X","article-title":"A whole blood flow cytometric determination of platelet activation by unfractionated and low molecular weight heparin in vitro","volume":"108","author":"Klein","year":"2002","journal-title":"Thromb. Res."},{"key":"10.1016\/j.ejphar.2012.11.026_bib21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/4795","article-title":"Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits","volume":"5","author":"Levi","year":"1999","journal-title":"Nat. Med."},{"issue":"Suppl. 2","key":"10.1016\/j.ejphar.2012.11.026_bib22","first-page":"748","article-title":"Safety and tolerability of the oral factor Xa inhibitor, YM150 vs. warfarin in 1297 patients with nonvalvular atrial fibrillation: a dose confirmation study (OPAL-2)","volume":"9","author":"Lip","year":"2011","journal-title":"J. Thromb. Haemostasis"},{"issue":"Suppl 1","key":"10.1016\/j.ejphar.2012.11.026_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1055\/s-2000-9497","article-title":"Comparative pharmacokinetics of LMWHs","volume":"26","author":"Samama","year":"2000","journal-title":"Semin. Thromb. Hemostasis"},{"key":"10.1016\/j.ejphar.2012.11.026_bib24","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/01.CIR.96.9.2877","article-title":"Differential effects of anticoagulants on the activation of platelets ex vivo","volume":"96","author":"Schneider","year":"1997","journal-title":"Circulation"},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2012.11.026_bib25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000083080","article-title":"The role of ximelagatran in the treatment of venous thromboembolism","volume":"34","author":"Schulman","year":"2005","journal-title":"Pathophysiol. Haemostasis Thromb."},{"key":"10.1016\/j.ejphar.2012.11.026_bib26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0049-3848(98)00093-0","article-title":"Neutralase reverses the anti-coagulant but not the anti-thrombotic activity of heparin in a rabbit model of venous thrombosis","volume":"91","author":"Silver","year":"1998","journal-title":"Thromb. Res."},{"key":"10.1016\/j.ejphar.2012.11.026_bib27","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehr334","article-title":"RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome","volume":"32","author":"Steg","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2012.11.026_bib28","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1161\/01.CIR.96.7.2339","article-title":"Inhibition of arterial thrombosis by recombinant annexin V in a rabbit carotid artery injury model","volume":"96","author":"Thiagarajan","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2012.11.026_bib29","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/0092-8674(91)90261-V","article-title":"Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation","volume":"64","author":"Vu","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2012.11.026_bib30","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2165\/00003088-200342080-00004","article-title":"No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor","volume":"42","author":"Wahlander","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejphar.2012.11.026_bib31","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/01.CIR.97.3.251","article-title":"Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor","volume":"97","author":"Xiao","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2012.11.026_bib32","doi-asserted-by":"crossref","first-page":"6642","DOI":"10.1073\/pnas.95.12.6642","article-title":"Cloning and characterization of human protease-activated receptor 4","volume":"95","author":"Xu","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299912009570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299912009570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:08:52Z","timestamp":1745366932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299912009570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":32,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0014299912009570"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2012.11.026","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}